Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial(†)

BACKGROUND: To establish the role of antiemetic therapy with neurokinin-1 (NK(1)) receptor antagonists (RAs) in nonanthracycline and cyclophosphamide (AC)-based moderately emetogenic chemotherapy (MEC) regimens, this study evaluated single-dose intravenous (i.v.) fosaprepitant for the prevention of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Weinstein, C., Jordan, K., Green, S. A., Camacho, E., Khanani, S., Beckford-Brathwaite, E., Vallejos, W., Liang, L. W., Noga, S. J., Rapoport, B. L.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2016
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4684151/
https://ncbi.nlm.nih.gov/pubmed/26449391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv482
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items